3F80.F Q-linea AB (publ)

Healthcare Medical Devices Frankfurt Exchange
1.24 EUR
Close of Nov 11, 2026
1.20 2.70
Market cap
EUR 23.5M
P/E
-
P/B
0.10x
ROE
-50.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 3F80.F undervalued?

Graham number

The Graham number of Q-linea AB (publ) cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Q-linea AB (publ) fundamental analysis

No fundamental analysis for Q-linea AB (publ) yet.

Q-linea AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Q-linea AB (publ)

Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the…

Full company profile